

Research and Reviews: Journal of Pharmacology and Toxicological Studies

A Review on Zika Virus

Venl atesh K^{1*} and Ram Vinod ND²

¹AITAM, Vizag, Andhra Pradesh, India

²Sri Krishna Devaraya University, Anantapur, Andhra Pradesh, India

Review Article

Received: 28/03/2016

Accepted: 01/03/2016

Published:05/04/2016

*For Correspondence

Venkatesh k, Aditya Institute of Technology, Vizag, Andhra Pradesh, India.

E-mail: kemburuvenkates@outlook.com

INTRODUCTION

Zika virus is a mosquito-borne flavivirus that was initially recognized in Uganda in 1947 in monkeys through a method that observed yellow fever. It was later distinguished in people in 1952 in Uganda and the United Republic of Tanzania. The explosions of Zika virus disease have been recorded in Africa, the Americas, Asia and the Pacific. From the 1960s to 1980s, human diseases were found around Africa and Asia, regularly accompanied by mild sickness. The primary substantial outbreak of illness occurred by Zika infection was reported from the Island of Yap. In the month of July, 2015 Brazil describes a partnership between Zika virus infection and Guillain-Barré disorder. In the month of October 2015 again Brazil country announced an union between Zika virus infection and microcephaly (Figure 1)^[1-5].




Figure 1: Zika Virus

The explosive widespread of Zika virus infection happening throughout the South America, Central America, and the Caribbean (Figure 2) and possibly threatening the United States is the latest of four unpredicted entries of vital arthropod-borne viral infection in the Western Hemisphere from past 20 years^[5-20].



Figure 2: Zika virus affected countries.

SYMPTOMS

The most widely recognized indications of Zika virus disease are fever, rash, joint agony and red eyes (Figure 3).

Suffering areas: Back portion of eyes, joints or muscles

Entire body: Tiredness, High fever, chills, loss of appetite, or sweating

Also common: Eye redness, cerebral pain, skin rash, or vomiting



Figure 3: Zika virus Symptoms

CASE FINDING

We recognized 185 instances of suspected Zika virus disease. Among these, 49 (26%) were affirmed and 59 (32%) were predictable cases. Acute-stage serum tests were gathered within 10 days after the onset of sickness from 45 of the 49 individuals with affirmed infection (92%), and Zika virus RNA was identified in 15 of these 45 patients (33%). No dengue virus RNA was recognised in any of the 137 acute-stage serum sample solutions tested (45 of these 137 patients affected confirmed Zika virus disease, 51 had probable disease, and 41 had suspected disease) [21-28].

The date of indication onset among patients with confirmed or predictable disease extended from April 15 to July 14. The number of cases peaked in late May and died down toward the beginning of July. The median age of patients with confirmed or predictable disease was 36 years (range, 1 to 76); among these 76 patients 66 of these patients (61%) were female [29-40].

The general attack rate for affirmed and plausible Zika virus disease observed among patients exhibiting to health care services was 14.6 per 1000 Yap inhabitants [41-51]. The attack rates vary from 3.6 per 1000 population in both of the Kanifay and the Gilman municipalities to 21.5 per 1000 population in Tomil region. The sex-specific attack rates were 17.9 per 1000 females and 11.4 per 1000 males. Cases happened among all age groups, yet the frequency of affirmed and probable Zika virus disease observed by medical services was most elevated among persons 55 to 59 years old.

HOW ARE YOU TESTED FOR ZIKA

There are two approaches to test for Zika Virus disease. One test searches for pieces of the virus' genetic code in individuals with dynamic diseases. But after the body clears the infection, which takes around 2 weeks after indications show up, that test won't work ^[51-56].

On March 18, the FDA approved most advanced version of this test that can recognize whether a person has dengue, chikungunya, or Zika, as opposed to doing three unique tests. The new form will be sent to qualified labs, the CDC says ^[57].

Around 80% of people affected with Zika don't have indications, numerous individuals don't know when they were affected and would not be desirable for this test ^[58,59].

Another test conducted for proteins called antibodies which are produces or generated by the immune system to act against the virus. It can find out antibodies in the blood up to 3 months after a person got infected ^[60-70].

PROTECTIVE MEASURES

If you plan to travel in affected areas, maintain distance by utilizing mosquito repellent from mosquito bites for the full day. Additionally, wear full-sleeved shirts and long jeans or laboratory dress code, both inside and outside. The mosquitoes that spreads Zika are aggressive daytime biters often frequently discovered inside, which we're not used to in the U.S.

Indeed, even those individuals who don't know that, they have Zika can spread the disease. Weaver suggested to people who have travelled to affected areas should be checked properly against mosquito bites when they return home, particularly in the first 10 days ^[71-85].

It is essential to cover, void or clean potential mosquito reproducing sites in and around the houses like cans, drums, pots, drains, and utilized tyres. Groups should support nearby government endeavours to decrease mosquitoes in their territory. Health care officials may also instruct that sprinkle of insecticides be carried out.

TREATMENT

There's no treatment, however Adalja says many people with indications do well with over-the-counter drugs for aches and pains. The infection generally runs its course within a week or somewhere in the vicinity ^[86-93].

Zika virus disease is normally mild and requires no particular treatment. People affected with Zika virus should get plenty of rest, drink enough liquids, and treat agony and fever with basic medications. If symptoms increase more, they should go for medical care and proper counsel. Present there is no vaccine available for Zika Virus disease.

REFERENCES

1. Ceron Ccrrasco JP, et al. Application of Computational Drug Discovery Techniques for Designing New Drugs against Zika Virus. *Drug Des.* 2016;5:e131.
2. Solomon IH, et al. Neuropathology of Zika Virus Infection. *J Neuroinfect Dis.* 2016;7:220.
3. Konda S, et al. The Evolution and Challenge of the *Zika virus* and its Uncharted Territory in the Neurological Realm. *J Neuroinfect Dis.* 2016;7:215.
4. Bandameedi R. Recent Outbreak of Zika Virus Threat for Pregnant Women. *Clin Pharmacol Biopharm.* 2016;5:157.
5. Silva DME, et al. Zika Virus Infection: New Findings Related to Neurological Complications . *J Neonatal Biol.* 2016;5:219.
6. Dolan SM, et al. Decision Making in the Face of Uncertainty: Perinatal Zika Virus Infection. *J Preg Child Health.* 2016;3:250.
7. Gulich GA. Epidemiology, Driving Factors, Transmission and Control Options of Zika Virus: A Review. *J Infect Dis Ther.* 2016;4:278.
8. Molina NB and Basualdo JA. Zika virus in the Americas: A New Global Health Emergency. *J Med Microb Diagn.* 2016;5:e132.
9. Weltman JK. An Immuno-Bioinformatic Analysis of Zika virus (ZIKV) Envelope E Protein. *J Med Microb Diagn.* 2016;5:228.
10. Awasthi S. Zika Virus: Prospects for the Development of Vaccine and Antiviral Agents. *J Antivir Antiretrovir.* 2016;8:LXI-LXIII.
11. Wickramasinghe NC and Steele EJ. Dangers of Adhering to an Obsolete Paradigm: Could Zika Virus Lead to a Reversal of Human Evolution. *Astrobiol Outreach.* 2016;4:147.
12. Musso D and Nhan TX. Emergence of Zika Virus. *Clin Microbiol.* 2015; 4:222.
13. Olson JG, et al. A survey for arboviral antibodies in sera of humans and animals in Lombok, Republic of Indonesia. *Ann Trop Med Parasitol.* 1983;77:131-137.
14. Morens DM and Fauci AS. Zika Virus Infection and Zika-Associated Fetal Infection/Microcephaly: General Update to Chapter. *Arthropod-Borne and Rodent-Borne Virus Infections.* 2016.
15. Tsai TF. Congenital arboviral infections: Something new, something old. *Pediatrics.* 2006;117:936.
16. Mlakar J, et al. Zika virus associated with microcephaly. *New England Journal of Medicine.* 2016;10:374: 951-958.

17. Creese C. Press Release: Expansion of Oxitec's Vector Control Solution in Brazil Attacking Source of Zika Virus and Dengue Fever after Positive Program Results. 2016.
18. Dick GW, et al. Zika virus (I) Isolations and serological specificity. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1952;46:509-520.
19. Pan American Health Organization. Zika virus infection. Washington DC.
20. BBC News. Zika virus: pp to four million Zika cases predicted. 2016.
21. BBC News. Zika virus: rumours and theories fuel 'information war'. 2016.
22. Vogel G, et al. Zika virus: your questions answered. 2016.
23. Carroll MW, et al. Temporal and spatial analysis of the 2014-2015 Ebola virus outbreak in West Africa. *Nature*. 2015;524:97-101.
24. Kuno G and Chang GJ. Full-length sequencing and genomic characterization of Bagaza, Kedougou, and Zika viruses. *Archives of Virology*. 2007;152:687-696.
25. van den Hurk AF, et al. Emerging tropical diseases in Australia. Part 4. Mosquito borne diseases. *Annals of Tropical Medicine and Parasitology*. 2010;104:623-640.
26. Foy BD, et al. Probable non-vector-borne transmission of Zika virus, Colorado, USA. *Emerging Infectious Diseases*. 2011;17:880-882.
27. Musso D, et al. Potential sexual transmission of Zika virus. *Emerging Infectious Diseases*. 2015;21:359.
28. Ginier M, et al. Zika without symptoms in returning travellers: what are the implications. *Travel Medicine and Infectious Disease*. 2016;14:16-20.
29. Centers for Disease Control and Prevention. Zika virus – symptoms, diagnosis & treatment. 2016.
30. Cao-Lormeau VM, et al. Zika virus, French Polynesia, South Pacific, 2013. *Emerging Infectious Diseases* 2014;20:1085-1086.
31. Meaney DD, et al. Zika virus and pregnancy: what obstetric health care providers need to know. *Obstetrics and Gynecology*. 2016.
32. Fauci AS and Morens DM. Zika virus in the Americas – yet another arbovirus threat. *New England Journal of Medicine*. 2016;374:601-604.
33. U S National Library of Medicine. CDC broadens Zika virus travel alert for pregnant women. 2016.
34. Ishikawa T, et al. A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available. *Vaccine*. 2014;32:1326-1337.
35. Holpuch A. Obama to seek \$1.8bn from Congress to combat Zika virus. 2016.
36. Mahalingam S and Rolph M. Here's why we don't have a vaccine for Zika (and other mosquito-borne viruses). *The Conversation*. 2016.
37. Schuler FL, et al. Possible association between Zika virus infection and microcephaly - Brazil, 2015. *Morbidity and Mortality Weekly Report*. 2016;65:59-62.
38. Calvet G, et al. Detection and sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in Brazil: a case study. *Lancet Infectious Diseases*. 2016.

39. Yasuno M and Tonn RJ. A study of biting habits of *Aedes aegypti* in Bangkok, Thailand. *Bulletin of the World Health Organization*. 1990;43:319-325.
40. Hanna JN, et al. Dengue in north Queensland, 2002. *Communicable Diseases Intelligence Quarterly Report*. 2003;27:384-389.
41. Russell RC, et al. Dengue and climate change in Australia: predictions for the future should incorporate knowledge from the past. *Medical Journal of Australia*. 2009;190:265-268.
42. Viennet E, et al. Epidemiology of dengue in a high-income country: a case study in Queensland, Australia. *Parasites & Vectors*. 2014;7:379.
43. Muir LE and Kay BH. *Aedes aegypti* survival and dispersal estimated by mark-release-recapture in northern Australia. *American Journal of Tropical Medicine and Hygiene*. 1998;58:277-282.
44. Gyawali N, et al. Knowledge, attitude and recommendations for practice regarding dengue among the resident population of Queensland, Australia. *Asian Pacific Journal of Tropical Biomedicine* In press. 2016.
45. American Mosquito Control Association. Why we need mosquito control. 2014.
46. Florida Medical Entomology Laboratory. Mosquito management. *Mosquito Information*. 2007.
47. World Health Organization. Handbook for Integrated Vector Management. Geneva: WHO. 2012.
48. Russell PK. The Zika Pandemic - A Perfect Storm?. *PLoS Negl Trop Dis*. 2016;10:e0004589.
49. Clyde KJL, et al. Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. *Journal of Virology*. 2006;80:11418-11431.
50. Lazear HM, et al. A Mouse Model of Zika Virus Pathogenesis. *Cell Host Microbe*. 2016;19:720-730.
51. Shan C, et al. An Infectious cDNA Clone of Zika Virus to Study Viral Virulence, Mosquito Transmission, and Antiviral Inhibitors. *Cell Host Microbe*. 2016;19:891-900.
52. Zmurko J, et al. The Viral Polymerase Inhibitor 7-Deaza-2'-C-Methyladenosine Is a Potent Inhibitor of In Vitro Zika Virus Replication and Delays Disease Progression in a Robust Mouse Infection Model. *PLoS Negl Trop Dis*. 2016; 10:e0004695.
53. Eyer L, et al. Nucleoside inhibitors of Zika virus. *J Infect Dis*. 2016.
54. Navarro FJ, et al. In silico discovery of a compound with nanomolar affinity to antithrombin causing partial activation and increased heparin affinity. *Journal of Medicinal Chemistry*. 2012;55:6403-6412.
55. Sánchez LI, et al. High-throughput parallel blind virtual screening using BINDSURF. *BMC Bioinformatics*. 2012;13:1.
56. Ravindranath PA, et al. AutoDockFR: Advances in Protein-Ligand Docking with Explicitly Specified Binding Site Flexibility. *PLoS Comput Biol*. 2015;11:e1004586.
57. Rentzsch R and Renard BY. Docking small peptides remains a great challenge: an assessment using AutoDock Vina. *Briefings in Bioinformatics*. 2015.
58. DeLuca S, et al. Fully Flexible Docking of Medium Sized Ligand Libraries with RosettaLigand. *PLoS One*. 2015;10: e0132508.

59. Kharkar, et al. Discovery of Anti-Ebola Drugs: A Computational Drug Repositioning Case Study. *RSC Adv.* 2016;6:26329-26340.
60. Ma J, et al. Deep neural nets as a method for quantitative structure–activity relationships. *Journal of Chemical Information and Modeling.* 2015;55:263-274.
61. Hughes TB, et al. Modeling epoxidation of drug-like molecules with a deep machine learning network. *ACS Central Science.* 2015;1:168-180.
62. Ekins S, et al. Open drug discovery for the Zika virus. *F1000Research.* 2016;5:150.
63. Ekins S, et al. Illustrating and homology modeling the proteins of the Zika virus. *F1000Research.* 2016;5:275.
64. Kirk DB and Wen-MeiWH. Programming massively parallel processors: a hands-on approach. *Newnes.* 2012.
65. Wu JC, et al. A GPU-based approach to accelerate computational protein-DNA docking. *Computing in Science & Engineering.* 2012;3:20-29.
66. Okada SK, et al. “GPU acceleration of Monte Carlo simulation at the cellular and DNA levels.” *Innovation in Medicine and Healthcare.* 2016.
67. Brasil PPereira JP, et al. Zika virus infection in pregnant women in Rio de Janeiro-preliminary report. *N Engl J Med.*
68. Carteaux G, et al. Zika virus associated with meningoencephalitis. *N Engl J Med* 2016;374:1595-1596
69. Musso D, et al. Potential sexual transmission of Zika virus. *Emerg Infect Dis.* 2015;21:359-361
70. Mlakar J, et al. Zika virus associated with microcephaly. *N Engl J Med.* 2016;374:951-958
71. Sarno M, et al. Zika virus infection and stillbirths: a case of hydrops fetalis, hydranencephaly and fetal demise. *PLoS Negl Trop Dis.* 2016;10:e0004517-e0004517.
72. Miner JJ, et al. Zika virus infection during pregnancy in mice causes placental damage and fetal demise. *Cell.* 2016;165:1081-1091.
73. Cugola FR, et al. The Brazilian Zika virus strain causes birth defects in experimental models. *Nature* 2016;534:267-271.
74. Li C, et al. Zika virus disrupts neural progenitor development and leads to microcephaly in mice. *Cell Stem Cell.* 2016.
75. Wu KY, et al. Vertical transmission of Zika virus targeting the radial glial cells affects cortex development of offspring mice. *Cell Res.* 2016;26:645-654.
76. Grant A, et al. Zika virus targets human STAT2 to inhibit type I interferon signaling. *Cell Host Microbe* 2016;19:882-890.
77. de Paula Freitas B, et al. Ocular findings in infants with microcephaly associated with presumed Zika virus congenital infection in Salvador, Brazil. *JAMA Ophthalmol.* 2016.
78. Bayer A, et al. Type III interferons produced by human placental trophoblasts confer protection against Zika virus infection. *Cell Host Microbe.* 2016;19:705-712.

79. Quicke KM, et al. Zika virus infects human placental macrophages. *Cell Host Microbe*. 2016.
80. Nowakowski TJ, et al. Expression analysis highlights AXL as a candidate Zika virus entry receptor in neural stem cells. *Cell Stem Cell*. 2016;18:591-596.
81. Dick GW, et al. Zika virus. I. Isolations and serological specificity. *Trans R Soc Trop Med Hyg* 1952;46:509-520.
82. Cao-Lormeau VM, et al. Zika virus, French Polynesia, South Pacific, 2013. *Emerg Infect Dis*. 2014;20:1085-1086.
83. Duffy MR, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. *N Engl J Med*. 2009;360:2536-2543.
84. Musso D, et al. Rapid spread of emerging Zika virus in the Pacific area. *Clin Microbiol Infect*. 2014;20:595-596. Zika virus outbreaks in the Americas. *Wkly Epidemiol Rec* 2015;90:609-610.
85. Lanciotti RS, et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. *Emerg Infect Dis*. 2008;14:1232-1239.
86. Lanciotti RS, et al. Phylogeny of Zika virus in western hemisphere. *Emerg Infect Dis*. 2015.
87. Besnard M, et al. Evidence of perinatal transmission of Zika virus, French Polynesia, December 2013 and February 2014. *Euro Surveill* 2014;19.
88. Oliveira Melo AS, et al. Zika virus intrauterine infection causes fetal brain abnormality and microcephaly: tip of the iceberg? *Ultrasound Obstet Gynecol* 2016;47:6-7.
89. Mlakar J, et al. Zika virus associated with microcephaly. *N Engl J Med*. 2016;374:951-958.
90. Brasil P, et al. Zika virus infection in pregnant women in Rio de Janeiro-preliminary report. *N Engl J Med*.
91. Interim guidelines for pregnant women during a Zika virus outbreak -United States, 2016. *MMWR Morb Mortal Wkly Rep*. 2016;65:30-33.
92. Zika virus infection: global update on epidemiology and potentially associated clinical manifestations. *Wkly Epidemiol Rec*. 2016;91:73-81.
93. Rapid risk assessment: Zika virus epidemic in the Americas: potential association with microcephaly and Guillain-Barre syndrome. Stockholm: European Center for Disease Prevention and Control. 2015.
94. Särndal CE and Lundström S. Estimation in surveys with nonresponse. West Sussex, United Kingdom: John Wiley. 2005.
95. Halstead SB, et al. Original antigenic sin in dengue. *Am J Trop Med Hyg*. 1983;32:154-156.
96. Inouye S, et al. "Original antigenic sin" phenomenon in experimental flavivirus infections of guinea pigs: studies by enzyme-linked immunosorbent assay. *Microbiol Immunol*. 1984;28:569-574.
97. Mostashari F, et al. Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. *Lancet*. 2001;358:261-264.
98. Nogueira RM, et al. Levels of IgM antibodies against dengue virus in Rio de Janeiro, Brazil. *Res Virol*. 1992;143:423-427.

99. Roehrig JT, et al. Persistence of virus-reactive serum immunoglobulin M antibody in confirmed West Nile virus encephalitis cases. *Emerg Infect Dis.* 2003;9:376-37.
- 100 Prince HE, et al. Development and persistence of West Nile virus-specific immunoglobulin M (IgM), IgA, and IgG in viremic blood donors. *J Clin Microbiol.* 2005;43:4316-4320.